The U.S. Food and Drug Administration has agreed to review Sanofi and Regeneron Pharmaceuticals’ request for a label extension for Dupixent (dupilumab) to include it as an add-on treatment for certain adults with uncontrolled chronic obstructive pulmonary disease (COPD). The therapy’s potential sixth indication in the U.S.
The U.S. Food and Drug Administration (FDA) for the first time has cleared a fingertip pulse oximeter for home use as a medical device that consumers — including people with chronic obstructive pulmonary disease (COPD) — can use to check their blood oxygen levels. The device, MightySat Medical from…
Travel times limit access to pulmonary rehabilitation programs to help people with chronic lung conditions, such as chronic obstructive pulmonary disease (COPD), a U.S. report revealed. Data showed about 80% of people live within a 30-minute drive of a rehabilitation site, mostly those who reside within major urban and…
A Phase 2a clinical trial of AstraZeneca’s experimental therapy mitiperstat is now recruiting adults with moderate to severe chronic obstructive pulmonary disease (COPD) at a study site in Choctaw, Oklahoma. The Care Access research site is among nearly 20 study centers in the U.S., located across 11…
Pulmonary (lung) rehabilitation nearly halves the odds of people with chronic obstructive pulmonary disease (COPD) experiencing an exacerbation, and it also cuts the risk of dying by about one-third, a study in Korea found. The study, “Pulmonary Rehabilitation Is Associated With Decreased Exacerbation and Mortality in Patients With…
Scientists at NextCure have developed a monoclonal antibody targeting the protein VSTM-1, which the company hopes to develop as a treatment for inflammatory lung disorders such as chronic obstructive pulmonary disease (COPD). “We believe we have a real opportunity to change the standard of care in…
Yupelri (revefenacin) is not superior to Spiriva (tiotropium) at improving lung function in adults with severe chronic obstructive pulmonary disease (COPD), according to data from a Phase 4 clinical trial. The head-to-head study, called PIFR-2 (NCT05165485) and sponsored by Yupelri’s co-developers Theravance Biopharma and…
Two international Phase 3 clinical trials testing the investigational antibody itepekimab in people with chronic obstructive pulmonary disease (COPD) are continuing to enroll patients — specifically, former smokers — at hundreds of centers worldwide, with several new sites recently opened in the U.S. All of the new sites are…
The number of people worldwide with chronic obstructive pulmonary disease (COPD) is predicted to increase by 23% in three decades, amounting to nearly 600 million patients by 2050, according to a new study. The largest increase, by nearly 50%, is projected to be among women and people living in…
Treatment with Dupixent (dupilumab) — approved in the U.S. for five inflammatory conditions, to date — once again resulted in significantly fewer exacerbations, or periods of sudden symptom worsening, among people with moderate to severe chronic obstructive pulmonary disease (COPD) in the second of two similarly designed Phase 3…
Get regular updates to your inbox.